A Prospective Patient Reported Outcomes and Wearables Study in Myeloproliferative Neoplasms
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Study ID
- NCT06334913
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Myeloproliferative Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The investigators will assess the use of a smart phone app to monitor patient reported outcomes and record biometric data in patients with myeloproliferative neoplasms.
Key Dates
- First listed
- Mar 28, 2024
- Start date
- Apr 1, 2024
- Status verified
- Mar 2024
- Primary completion
- Apr 1, 2029
- Completion
- Apr 1, 2029
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: MPN patientsU.K. based adult patients with MPN diagnosis.
Primary Outcome Measure
Patient reported outcomes - Myeloproliferative Neoplasm-10 Total Symptom Score [ Time Frame: 5 years ]
Central Contacts
- Patrick Harrington, MBBS PhD+447946509718
- Amna Sheikh
Related Studies
- Project: Every Child for Younger Patients With CancerRecruiting · Children's Oncology Group · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesPHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Boston, Massachusetts
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas